Comply with new prices of 137 anti-cancer drugs or face action, says regulator

The National Pharmaceutical Pricing Authority (NPPA) has issued a stern warning to those who do not comply with the new prices set for 137 anti-cancer drugs, threatening them with penal action. The authority, operating under the Department of Pharmaceuticals, has requested State drug controllers to closely monitor the prices and submit their action taken reports by November 16.

The revised prices for these drugs came into effect on November 9, 2026, after a gazette order was issued on October 17, 2026. This order set the trade margin on these medicines at a maximum of 30%. The latest revised price lists have been uploaded on the NPPA website, along with the Pharma Sahi Daam app and portal, as per the Chemicals and Fertilizers Ministry.

All manufacturers, stockists, dealers, retailers, hospitals, and medical institutions have been instructed to comply with the revised prices and display the updated price lists prominently at their establishments and online platforms. The State Drug Controllers are tasked with ensuring strict compliance throughout the supply chain and healthcare facilities to ensure that the advantages of the new maximum retail prices (MRPs) reach the patients.

Any breach of this directive could result in overcharging proceedings under the Drugs and Pharmaceuticals (Control of Price) Order, 2013. Any complaints related to overcharging, shortages, or unavailability of medicines can be reported through the Pharma Sahi Daam app, portal, NPPA helpline (1800-111-255), or email at monitoring-nppa@gov.in.